Interesting Images

Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET/CT in a Patient Treated for Hodgkin Lymphoma

Simand, Celestine MD, PhD∗,†; Bund, Caroline MD∗,‡,§; Guffroy, Blandine MD∗,†,∥; Chaban, Vitaliy MD; Herbrecht, Raoul MD∗,†,∥

Author Information

From the ∗Institut de Cancérologie Strasbourg, Europe (ICANS)

Departments of †Hematology

‡Biophysics and Nuclear Medicine, University Hospital of Strasbourg

§ICube, Université de Strasbourg/CNRS, UMR 7357

∥Université de Strasbourg, Inserm UMR S1113/IRFAC

Intermediate Care Unit, Institut de Cancérologie Strasbourg, Europe (ICANS), Strasbourg, France.

Received for publication April 1, 2020; revision accepted April 27, 2020.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Raoul Herbrecht, MD, Department of Hematology, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67033 Strasbourg, France. E-mail: [email protected].

Clinical Nuclear Medicine 45(8):p 644-646, August 2020. | DOI: 10.1097/RLU.0000000000003144

Abstract

We report the results of 18F-FDG PET/CT in an asymptomatic case of COVID-19 infection. A 27-year-old woman underwent FDG PET/CT for revaluation of a stage IIIE B Hodgkin lymphoma after the fourth cycle of chemotherapy. It showed intense avid FDG subpleural mixed ground-glass and consolidative lesions, especially in the left lung. Because of this morpho-metabolic aspect and the epidemic context, a viral pneumopathy was suspected. The patient who was initially asymptomatic was admitted for fever 28 hours after the PET/CT. The nasopharyngeal swab was positive for COVID-19, and the outcome was favorable.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid